Kagota Satomi, Iwata Saki, Maruyama Kana, McGuire John J, Shinozuka Kazumasa
1 Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University , Nishinomiya, Japan .
2 Faculty of Medicine, Division of BioMedical Sciences, Memorial University , St. John's, Canada .
Metab Syndr Relat Disord. 2017 Jun;15(5):233-239. doi: 10.1089/met.2016.0146. Epub 2017 Mar 30.
Metabolic syndrome (MetS) facilitates the development of cardiovascular disease due to atherosclerosis, which is accelerated by defects of the vascular endothelium. Vascular dysfunction in response to nitric oxide (NO) occurs in the mesenteric arteries of an animal model of MetS, SHRSP.Z-Lepr/IzmDmcr (SHRSP.ZF) rats. Vascular responses to vasodilators are affected by perivascular adipose tissue (PVAT) that surrounds the outsides of arteries. In this study, we assessed the role of PVAT in vascular dysfunction observed in SHRSP.ZF.
To determine the effects of PVAT on vasodilators in SHRSP.ZF and control Wistar-Kyoto (WKY) rats, we used organ bath bioassay techniques to assay acetylcholine and nitroprusside-induced relaxations of isolated mesenteric arterial ring preparations with PVAT intact or removed.
A PVAT-mediated enhancement of relaxations induced by acetylcholine and nitroprusside occurred in SHRSP.ZF at 20 weeks of age, but not at 10 and 30 weeks, and did not occur in WKY. Furthermore, the enhancing effects of PVAT from SHRSP.ZF at 20 weeks could not be substituted by replacement with PVAT from either WKY or 30-week-old SHRSP.ZF, was inhibited by NO synthase inhibitor, and abolished by removal of the arteries' endothelium. Cyclic guanosine monophosphate (cGMP) accumulation elicited by nitroprusside was higher in SHRSP.ZF arteries with PVAT than arteries without PVAT at 20 weeks, but the enhancement of cGMP accumulation did not occur at 30 weeks.
PVAT may regulate arterial tone by releasing diffusible vasorelaxing factor(s), which, through endothelium-derived NO production, compensates for impaired vasodilations at early stages of MetS.
代谢综合征(MetS)会促进动脉粥样硬化所致心血管疾病的发展,而血管内皮缺陷会加速这一进程。在MetS动物模型SHRSP.Z-Lepr/IzmDmcr(SHRSP.ZF)大鼠的肠系膜动脉中,会出现对一氧化氮(NO)反应的血管功能障碍。血管对血管舒张剂的反应受围绕动脉外部的血管周围脂肪组织(PVAT)影响。在本研究中,我们评估了PVAT在SHRSP.ZF中观察到的血管功能障碍中的作用。
为确定PVAT对SHRSP.ZF和对照Wistar-Kyoto(WKY)大鼠血管舒张剂的影响,我们使用器官浴生物测定技术,检测完整或去除PVAT的离体肠系膜动脉环制剂对乙酰胆碱和硝普钠诱导的舒张反应。
20周龄的SHRSP.ZF中出现了PVAT介导的乙酰胆碱和硝普钠诱导舒张增强,但10周和30周龄时未出现,WKY中也未出现。此外,20周龄SHRSP.ZF的PVAT的增强作用不能被WKY或30周龄SHRSP.ZF的PVAT替代,一氧化氮合酶抑制剂可抑制该作用,去除动脉内皮可消除该作用。20周时,有PVAT的SHRSP.ZF动脉中硝普钠引起的环磷酸鸟苷(cGMP)积累高于无PVAT的动脉,但30周时未出现cGMP积累增强。
PVAT可能通过释放可扩散的血管舒张因子来调节动脉张力,这些因子通过内皮源性NO的产生,在MetS早期阶段补偿受损的血管舒张。